Trial Profile
Apatinib for non-first-line treatment as an anti-angiogenesis agent in metastatic cancer:an open-label,single-arm phase II trial
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 06 Nov 2017 New trial record